Coherus BioSciences (CHRS) to Release Quarterly Earnings on Thursday

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) will release its earnings data after the market closes on Thursday, May 9th. Analysts expect Coherus BioSciences to post earnings of ($0.05) per share for the quarter. Investors that are interested in participating in the company's conference call can do so using this link.

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) last released its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.39). The firm had revenue of $91.52 million during the quarter, compared to analyst estimates of $105.30 million. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Coherus BioSciences Stock Up 5.3 %

Shares of NASDAQ CHRS traded up $0.11 during midday trading on Thursday, hitting $2.17. The stock had a trading volume of 992,384 shares, compared to its average volume of 3,580,298. The company has a market capitalization of $246.30 million, a price-to-earnings ratio of -0.84 and a beta of 0.56. Coherus BioSciences has a 1-year low of $1.43 and a 1-year high of $8.22. The company has a fifty day moving average price of $2.28 and a 200 day moving average price of $2.44.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CHRS shares. HC Wainwright cut their target price on Coherus BioSciences from $13.00 to $11.00 and set a "buy" rating on the stock in a research report on Wednesday, March 20th. Truist Financial cut their target price on Coherus BioSciences from $12.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, January 23rd. Finally, Robert W. Baird cut their target price on Coherus BioSciences from $11.00 to $9.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 23rd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $9.29.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.